Tech Company Financing Transactions
Atsena Therapeutics Funding Round
Atsena Therapeutics, based in Durham, secured $55 million in funding from Sofinnova Ventures, Abingworth and Hatteras Venture Partners.
Transaction Overview
Company Name
Announced On
12/17/2020
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
280 S Mangum St. 350
Durham, NC 27701
USA
Durham, NC 27701
USA
Phone
Website
Email Address
Overview
ATSENA THERAPEUTICS is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. The company has an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Patrick Ritschel
Chief Operating Officer
Nasser Hassan
Chief Scientific Officer
Shannon Boye
Chief Technical Officer
Sanford Boye
VP - Manufacturing
Michael Kelly
Browse more venture capital transactions:
Prev: 12/17/2020: BigID venture capital transaction
Next: 12/17/2020: Carlsmed venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records on this site are derived from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs